The primary Phase 1 purpose of this study was to assess overall safety, tolerability and recommended Phase 2 dose (RP2D) of APL-101.
The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers associated with c-Met amplifications; individuals with cancers associated with c-Met fusion.
Inclusions/Exclusions: Able to understand and comply with study procedures, understand the risks involved, and provide written informed consent. Can’t have hypersensitivity to APL-101, excipients of the drug product, or other components of the study treatment regimen.